Newsroom | 4632 results
Sorted by: Latest
-
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced a collaboration to automate manufacturing of lead SonomaBio® program, SBT-77-7101, on the Cellares Cell Shuttle. SBT-77-7101 is an autologous CAR-Treg cell therapy in Phase...
-
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on COR1, the Company’s allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expert...
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan...
-
Cord Blood Council Earns 501(c)(3) Nonprofit Status and Opens Public Donations to Strengthen the Nation’s Public Cord Blood Banks
SEATTLE--(BUSINESS WIRE)--The Cord Blood Council (CBC), a capacity-building nonprofit supporting the nation’s public cord blood banks, today announced that it has received federal 501(c)(3) tax-exempt status and is now accepting tax-deductible donations from the public. Gifts can be made at cbcouncil.org/donate. The milestone broadens the community support behind the organization’s mission: strengthening and unifying the public cord blood banks that supply the life-saving stem cells used in tra...
-
Independent Recognition Reinforces Auragens' Position as a Global Leader in Regenerative Medicine
LAS VEGAS & PANAMA CITY, Panama--(BUSINESS WIRE)--Auragens today announced it has been named Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, becoming the first organization to receive the publication's highest distinction for two consecutive years. While the award recognizes excellence in patient care, it also reflects a broader transformation taking place within regenerative medicine—one in which scientific rigor, manufacturing quality, regulatory oversight, and integrated...
-
Takara Bio USA, Inc. Announces the Retirement of Carol Lou, Appoints Andrew Farmer as President and CEO
SAN JOSE, Calif.--(BUSINESS WIRE)--President & CEO of Takara Bio USA Carol Lou announces she is retiring after 20 years of service, with Andrew Farmer as her successor....
-
Neo7Bioscience Announces Precision Signal Interception as a Transformative Approach to Pancreatic Cancer Treatment, Surpassing Limitations of Conventional RAS Pathway Suppression
DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neo7Bioscience Announces Precision Signal Interception for Pancreatic Cancer Treatment Beyond Conventional RAS Pathway Suppression...
-
Riassunto: STEMCELL Technologies e CCRM collaborano per ampliare l'accesso a linee iPSC conformi alle norme GMP e RUO per lo sviluppo della terapia cellulare
VANCOUVER, British Columbia e TORONTO--(BUSINESS WIRE)--STEMCELL Technologies e il Centre for Commercialization of Regenerative Medicine (CCRM) oggi ha annunciato una collaborazione per ampliare l'accesso a materiali di partenza di alta qualità derivati da cellule staminali pluripotenti indotte umane (iPSC), offrendo agli sviluppatori di terapie cellulari di tutto il mondo un percorso più rapido e meno rischioso dalla ricerca alla clinica. Il testo originale del presente annuncio, redatto nella...
-
Samenvatting: STEMCELL Technologies en CCRM gaan samenwerken om de toegang tot op elkaar afgestemde GMP- en RUO-iPSC-lijnen voor de ontwikkeling van celtherapieën te vergroten
VANCOUVER, Brits-Columbia & TORONTO--(BUSINESS WIRE)--STEMCELL Technologies en het Centre for Commercialization of Regenerative Medicine (CCRM) hebben vandaag een samenwerking aangekondigd om de toegang tot hoogwaardig uitgangsmateriaal in de vorm van menselijke geïnduceerde pluripotente stamcellen (iPSC’s) te vergroten. Dit geeft ontwikkelaars van celtherapieën wereldwijd een snellere en minder risicovolle oplossing van onderzoek naar de klinische praktijk. Deze bekendmaking is officieel gelde...
-
STEMCELL Technologies et le CCRM s’associent pour élargir l’accès à des lignées de CSPi conformes aux normes BPF et à des lignées de CSPi RUO appariées, en vue du développement de thérapies cellulaires
VANCOUVER, Colombie-Britannique et TORONTO--(BUSINESS WIRE)--STEMCELL Technologies et le Centre for Commercialization of Regenerative Medicine (CCRM) ont annoncé aujourd’hui un partenariat visant à élargir l’accès à des matériaux de départ de haute qualité issus de cellules souches pluripotentes induites (CSPi) humaines, offrant ainsi aux développeurs de thérapies cellulaires du monde entier une voie plus rapide et moins risquée pour passer de la recherche à la pratique clinique. Dans le cadre...
